Argos Therapeutics, Inc. filed a plan of liquidation with related disclosure statement in the US Bankruptcy Court on March 15, 2019. As per the plan filed, administrative claims, priority tax claims, professional fee claims, secured tax claims, other secured claims and other priority claims will be paid in full in cash. Pharmstandard secured note claim of $7.16 million will be recovered 99%, i.e., $7.09 million in the form of cash. General unsecured claims in the range of $6.65 million to $19.04 million will be recovered in the range of 72% to 27%, i.e., $5.14 million in the form of cash. Interests shall be cancelled. The plan will be funded through cash in hand and sale of assets. Argos Therapeutics, Inc. filed revised plan of liquidation with related disclosure statement in the US Bankruptcy Court on April 4, 2019. As per the plan filed, there is no change in the treatment of any claim class.